

DETAILED ACTION

Applicant canceled **Claims 6 and 7**. Applicant amended **Claims 1 and 8** via an Examiner's Amendment which appears below. Therefore, **Claims 1-5, 8, and 9** are pending in this application. Furthermore, **Claims 1-5, 8, and 9** are in condition for allowance.

Information Disclosure Statement

The information disclosure statement (IDS) submitted on June 1, 2006 was correctly filed. The submission is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement was considered by the Examiner.

Examiner's Amendment

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to Applicant, an amendment may be filed as provided by 37 C.F.R. § 1.312. To ensure consideration of such an amendment, it must be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Catherine McCarty on August 8, 2006. The application has been amended as follows:

1. **Claim 1**, p. 1, line 14: After the words, "R³ is aryl or heteroaryl each of which is optionally substituted by one or more substituents independently selected from hydrogen, halogen, CN," delete the word, "nitro,".
2. **Claim 1**, p. 3, lines ³⁻⁵~~4-5~~: After the words, "In the context of the present specification, unless otherwise indicated, an alkyl or alkenyl group or an alkyl or alkenyl moiety in a substituent group may be linear, branched or", delete the word, "cyclic;" and insert

ya 9/20